FOI 6303 - Breast Cancer Treatment

Date: 13 October 2020 to 13 October 2023

I am researching the incidence and treatment of breast cancer.  Could you please provide the number of patients that you have treated in the past three months with the following:

  • Abemaciclib + Anastrozole/Exemestane/Letrozole
  • Abemaciclib + Fulvestrant
  • Alpelisib + Fulvestrant
  • Atezolizumab
  • Bevacizumab
  • Eribulin
  • Everolimus + Exemestane
  • Fulvestrant as a single agent
  • Gemcitabine + Paclitaxel
  • Lapatinib
  • Neratinib
  • Olaparib
  • Palbociclib + Anastrozole/Exemestane/Letrozole
  • Palbociclib  + Fulvestrant
  • Pertuzumab + Trastuzumab + Docetaxel
  • Ribociclib + Anastrozole/Exemestane/Letrozole
  • Ribociclib + Fulvestrant
  • Talazoparib
  • Transtuzumab + Paclitaxel
  • Transtuzumab as a single agent
  • Trastuzumab emtansine
  • Any other active systemic anti-cancer therapy
  • Request ID:
    6303
  • Category:
    Clinical - Drugs
  • Response:

    October 2020

    Thank you for your recent request under the Freedom of Information Act 2000.

    The information you have requested is as follows:

    I am researching the incidence and treatment of breast cancer.  Could you please provide the number of patients that you have treated in the past three months with the following:

    Medway NHS Foundation Trust can confirm that the number of patients treated for breast Cancer from 01/06/2020 to 31/08/2020 is 155 patients:

    • Abemaciclib + Anastrozole/Exemestane/Letrozole=0
    • Abemaciclib + Fulvestrant=0
    • Alpelisib + Fulvestrant =0
    • Atezolizumab =<5
    • Bevacizumab=0
    • Eribulin= <5
    • Everolimus + Exemestane=<5
    • Fulvestrant as a single agent=0
    • Gemcitabine + Paclitaxel=0
    • Lapatinib =0
    • Neratinib =0
    • Olaparib = 0
    • Palbociclib + Anastrozole/Exemestane/Letrozole=29
    • Palbociclib  + Fulvestrant=0
    • Pertuzumab + Trastuzumab + Docetaxel=5
    • Ribociclib + Anastrozole/Exemestane/Letrozole=<5
    • Ribociclib + Fulvestrant=0
    • Talazoparib =0
    • Transtuzumab + Paclitaxel=<5
    • Transtuzumab as a single agent=20
    • Trastuzumab emtansine =9
    • Any other active systemic anti-cancer therapy=84